CAR T-Cell Immunotherapy for ALL An article about an immunotherapy approach that involves engineering patients’ own immune cells to recognize and attack their tumors. http://ift.tt/2euVV3z Nanoparticles Create Effective CAR T Cells in Mice A Cancer Currents blog on the development of a method to genetically engineer cancer-fighting immune cells, known as CAR T cells, in living animals using nanoparticles that carry DNA. http://ift.tt/2q7WBEQ CAR T-Cell Therapy for Multiple Myeloma A Cancer Currents blog on results presented at the American Society of Clinical Oncology annual meeting from two early-phase trials testing immune cells that were engineered to target a protein on myeloma cells called B-cell maturation antigen. http://ift.tt/2sjYS0K CAR T Cell Immunotherapy Promising in Refractory Leukemia | Center for Cancer Research B-cell acute lymphoblastic leukemia (B-ALL) is a common childhood malignancy that also affects young adults. Although current treatments have significant toxicities, children with chemotherapy susceptible subtypes have high survival rates. However, less than 10 percent of children and young adults with newly-diagnosed or recurrent B-ALL that is insensitive to therapy survive, and this rate has not budged in the last 20 years. http://ift.tt/2tIyB9v IN SITU IMAGING OF CAR T-CELLS | Innovative Molecular Analysis Technologies (IMAT) http://ift.tt/2v4RuXy Sipuleucel-T This page contains brief information about sipuleucel-T and a collection of links to more information about the use of this vaccine, research results, and ongoing clinical trials. http://ift.tt/2tIGFa5 Immune Cells in Blood Recognize Tumors NCI scientists have developed a novel strategy for identifying immune cells circulating in the blood that recognize specific proteins on tumor cells, a finding they believe may have potential implications for immune-based therapies. http://ift.tt/2caNGvY Pembrolizumab for Merkel Cell Carcinoma In a small clinical trial, more than half of the patients with an aggressive form of skin cancer called Merkel cell carcinoma responded to the immunotherapy drug pembrolizumab. http://ift.tt/2nAoJuB Circulating Multiple Myeloma Tumor Cells A Cancer Currents blog post about research showing that individual tumor cells in patients with multiple myeloma may provide important clues about the genetic drivers of their disease. http://ift.tt/2htn8F8 Childhood Hematopoietic Cell Transplantation (PDQ®)—Health Professional Version Expert-reviewed information summary about the use of hematopoietic cell transplantation in treating childhood cancer. http://ift.tt/2tILVeb

• CAR T-Cell Immunotherapy for ALL
  An article about an immunotherapy approach that involves engineering patients’ own immune cells to recognize and attack their tumors.
  http://ift.tt/2euVV3z
• Nanoparticles Create Effective CAR T Cells in Mice
  A Cancer Currents blog on the development of a method to genetically engineer cancer-fighting immune cells, known as CAR T cells, in living animals using nanoparticles that carry DNA.
  http://ift.tt/2q7WBEQ
• CAR T-Cell Therapy for Multiple Myeloma
  A Cancer Currents blog on results presented at the American Society of Clinical Oncology annual meeting from two early-phase trials testing immune cells that were engineered to target a protein on myeloma cells called B-cell maturation antigen.
  http://ift.tt/2sjYS0K
• CAR T Cell Immunotherapy Promising in Refractory Leukemia | Center for Cancer Research
  B-cell acute lymphoblastic leukemia (B-ALL) is a common childhood malignancy that also affects young adults. Although current treatments have significant toxicities, children with chemotherapy susceptible subtypes have high survival rates. However, less than 10 percent of children and young adults with newly-diagnosed or recurrent B-ALL that is insensitive to therapy survive, and this rate has not budged in the last 20 years.
  http://ift.tt/2tIyB9v
• IN SITU IMAGING OF CAR T-CELLS | Innovative Molecular Analysis Technologies (IMAT)
  http://ift.tt/2v4RuXy
• Sipuleucel-T
  This page contains brief information about sipuleucel-T and a collection of links to more information about the use of this vaccine, research results, and ongoing clinical trials.
  http://ift.tt/2tIGFa5
• Immune Cells in Blood Recognize Tumors
  NCI scientists have developed a novel strategy for identifying immune cells circulating in the blood that recognize specific proteins on tumor cells, a finding they believe may have potential implications for immune-based therapies.
  http://ift.tt/2caNGvY
• Pembrolizumab for Merkel Cell Carcinoma
  In a small clinical trial, more than half of the patients with an aggressive form of skin cancer called Merkel cell carcinoma responded to the immunotherapy drug pembrolizumab.
  http://ift.tt/2nAoJuB
• Circulating Multiple Myeloma Tumor Cells
  A Cancer Currents blog post about research showing that individual tumor cells in patients with multiple myeloma may provide important clues about the genetic drivers of their disease.
  http://ift.tt/2htn8F8
• Childhood Hematopoietic Cell Transplantation (PDQ®)—Health Professional Version
  Expert-reviewed information summary about the use of hematopoietic cell transplantation in treating childhood cancer.
  http://ift.tt/2tILVeb
• Another Cancer Cell Energy Source
  An NCI Cancer Currents blog post on a study showing that, instead of discarding lactate, cancer cells can use it to fuel biochemical reactions, support their growth.
  http://ift.tt/2emhkhP
• Conditional Reprogramming to Grow Cancer Cells
  An NCI Cancer Currents blog featuring Dr. Richard Schlegel discussing conditional reprogramming, a new cell culture technique for rapidly growing normal and tumor cells.
  http://ift.tt/2lpJlYA
• Avelumab Shrinks Merkel Cell Tumors
  An NCI Cancer Currents blog post about results from a phase II clinical trial showing durable tumor responses to the immunotherapy drug avelumab in patients with metastatic Merkel cell carcinoma.
  http://ift.tt/2cY0L79
• FDA Approves T-VEC to Treat Metastatic Melanoma
  The drug is the first oncolytic virus therapy to be approved.
  http://ift.tt/2tIPL6O
• Pancreatic Cancer Cells Rely on Neighbors for Nutrients
  An NCI Cancer Currents blog about a study which showed that pancreatic cancer cells instruct healthy cells around them to provide nutrients they need to survive and grow.
  http://ift.tt/2cYlqfS
• Plasma Cell Neoplasms (Including Multiple Myeloma)—Health Professional Version
  NCI's gateway for information about Multiple Myeloma and Other Plasma Cell Neoplasms.
  http://ift.tt/2tIr5LU
• Plasma Cell Neoplasms (Including Multiple Myeloma)—Patient Version
  Information about multiple myeloma and other plasma cell neoplasms: treatment, clinical trials, research, and statistics from the National Cancer Institute.
  http://ift.tt/2lMsWLl
• Study Tests Safer Stem Cell Transplant
  An NCI Cancer Currents blog about a study testing a potentially safer way to perform stem cell transplants for treating cancer and other diseases.
  http://ift.tt/2cmKYVh
• T-Cell Warriors—Equipped to Kill Cancer Cells | Center for Cancer Research
  When the body recognizes tumor cells as foreign, a natural immune response arises to attack them. Unfortunately, tumors have ways to evade immune surveillance systems and antitumor responses are often too weak to defeat the disease. Rather than relying on the body’s natural response, scientists can now manipulate a patient’s own immune cells so that they latch on to tumor cells by recognizing specific proteins on their surface. A type of immune cell that has been explored for this purpose is the killer (cytotoxic) T cell, which eliminates cells infected by viruses, damaged cells, and tumor cells.
  http://ift.tt/2v4JciG
• Patient-Derived Antibody Targets Tumor Cells
  An NCI Cancer Currents blog on an antibody derived from patients that killed tumor cells in cell lines of several cancer types and slowed tumor growth in mouse models of brain and lung cancer without evidence of side effects.
  http://ift.tt/2tICdZe
• Plasma Cell Neoplasms (Including Multiple Myeloma) Research
  Find research articles on plasma cell neoplasms (including multiple myeloma), which may include news stories, clinical trials, blog posts, and descriptions of active studies.
  http://ift.tt/2v4RtTu
• Immune-Cell Traps May Aid Cancer Metastasis
  A Cancer Currents blog post on a new study that suggests cancer cells may exploit a normal function of neutrophils, a type of immune cell, to help form metastatic tumors.
  http://ift.tt/2g5uEc1
• Avelumab First Approved Drug for Merkel Cell Carcinoma
  A Cancer Currents blog on the FDA’s first-ever approval of a drug for the rare skin cancer Merkel cell carcinoma and updated data on patients’ tumor responses.
  http://ift.tt/2oRj9F3
• Stem Cell-Based Tool Ranks Heart Toxicity of Cancer Drugs
  A Cancer Currents blog post on a new research study that uses a type of adult stem cell to assess the heart toxicity of cancer drugs known as tyrosine kinase inhibitors.
  http://ift.tt/2mMQfo4
• Pre-Stem Cell Transplant Treatment Regimen for AML, MDS
  A Cancer Currents blog on a study suggesting that an intensive preparatory regimen should be used for younger patients with AML undergoing a stem cell transplant.
  http://ift.tt/2qPMgwh
• Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)—Health Professional Version
  Expert-reviewed information summary about the treatment of plasma cell neoplasms (including multiple myeloma).
  http://ift.tt/2tIhHYM
• Signaling Enhances the Effectiveness of Cancer Immunotherapy
  Costimulatory signals regulate T cell exhaustion, affecting cancer immunotherapy.
  http://ift.tt/2v4JHJv
• Extracranial Germ Cell Tumors—Patient Version
  Information about extracranial germ cell tumor in children: treatment and clinical trials from the National Cancer Institute.
  http://ift.tt/2qjmf91
• Extracranial Germ Cell Tumors—Health Professional Version
  NCI's gateway for information about extracranial germ cell tumors.
  http://ift.tt/2rhUZVA
• Langerhans Cell Histiocytosis—Patient Version
  NCI's gateway for information about langerhans cell histiocytosis.
  http://ift.tt/2tI3oDj
• Langerhans Cell Histiocytosis—Health Professional Version
  NCI's gateway for information about langerhans cell histiocytosis.
  http://ift.tt/2v4xFQf
• Extragonadal Germ Cell Tumors—Patient Version
  Information about extragonadal germ cell tumor: treatment and clinical trials from the National Cancer Institute.
  http://ift.tt/2tIGGLb
• Extragonadal Germ Cell Tumors—Health Professional Version
  NCI's gateway for information about Extragonadal Germ Cell Tumor .
  http://ift.tt/2v504Wj
• CRISPR Gene-Editing Tool May Help Improve Cancer Immunotherapy
  A Cancer Currents blog about using the CRISPR gene-editing technology to genetically engineered immune cells and improve the ability of these cells to kill cancer cells in mice.
  http://ift.tt/2nJXCOY
• Expanding Immunotherapy to More Cancer Types
  Early studies explore ways to ‘fine tune’ immune cells to treat cancer.
  http://ift.tt/2qJLL7O
• Sonidegib Approved for Advanced Basal Cell Carcinoma
  FDA approval provides a new option for this hard-to-treat skin cancer.
  http://ift.tt/2v4QItY
• FDA Approval for Sipuleucel-T
  Information from the FDA about the approval of this drug and the clinical trials that led to the approval.
  http://ift.tt/2tICcEE
• DINO RNA Molecule Triggers Anticancer Response in Damaged Cells
  An NCI Cancer Currents blog post about a noncoding RNA called DINO, which helps accelerate the cellular self-destruct process that prevents tumor development.
  http://ift.tt/2f1saeZ
• DCB - Cancer Cell Biology Research
  Part of NCI's Division of Cancer Biology research portfolio, this research defines the biological basis for the differences between normal cells and cancer cells.
  http://ift.tt/2tIGFqB
• Stem Cell Transplants in Cancer Treatment
  Stem cell transplants are procedures that restore blood-forming stem cells in cancer patients who have had theirs destroyed by very high doses of chemotherapy or radiation therapy. Learn about the types of transplants and side effects that may occur.
  http://ift.tt/2v4WZ8F
• RAS - Target Identification - Cell Surfaces
  The goal of this group includes identifying proteins that are enriched or unique to the surfaces of cancer cells driven by mutant RAS genes.
  http://ift.tt/2tIPNvs
• Merkel Cell Carcinoma Treatment (PDQ®)—Health Professional Version
  Expert-reviewed information summary about the treatment of Merkel cell carcinoma.
  http://ift.tt/2v4ZqrT
• Merkel Cell Carcinoma Treatment (PDQ®)—Patient Version
  Expert-reviewed information summary about the treatment of Merkel cell carcinoma.
  http://ift.tt/2o5WPKS
• Hairy Cell Leukemia Treatment (PDQ®)—Health Professional Version
  Expert-reviewed information summary about the treatment of hairy cell leukemia.
  http://ift.tt/2oRFHtl
• Hairy Cell Leukemia Treatment (PDQ®)—Patient Version
  Expert-reviewed information summary about the treatment of hairy cell leukemia.
  http://ift.tt/2tIPO2u
• Langerhans Cell Histiocytosis Treatment (PDQ®)—Health Professional Version
  Expert-reviewed information summary about the treatment of childhood Langerhans Cell Histiocytosis.
  http://ift.tt/2v4QCSS
• Langerhans Cell Histiocytosis Treatment (PDQ®)—Patient Version
  Expert-reviewed information summary about the treatment of childhood Langerhans Cell Histiocytosis.
  http://ift.tt/2dl1HYF
• Renal Cell Cancer Treatment (PDQ®)—Health Professional Version
  Expert-reviewed information summary about the treatment of renal cell cancer.
  http://ift.tt/2v4QK54
• Renal Cell Cancer Treatment (PDQ®)—Patient Version
  Expert-reviewed information summary about the treatment of renal cell cancer.
  http://ift.tt/2tIPP6y
• FDA Approves Pembrolizumab to Treat Non-Small Cell Lung Cancer
  The drug is used to treat patients whose tumors express a protein called PD-L1.
  http://ift.tt/2eFrkjQ

http://ift.tt/2tIPPDA